{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.08","upperLimit":"17.29","value":"8.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"description":"Day 100 Treatment Related Mortality An exact 95% confidence interval will be provided.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive fludarabine phosphate IV over 30 minutes on days -5 to -2 and melphalan\\* IV over 30 minutes on day -2. Patients then undergo total-body irradiation on day -1 and allogeneic stem cell transplantation on day 0.\n\nNote: \\*Patients with chromosomal breakage syndromes, such as Fanconi anemia or dyskeratosis congenita, receive anti-thymocyte globulin IV over 4 hours on day -4 to -2 instead of melphalan.","id":"OG000","title":"Treatment (Reduced Intensity Allogeneic Stem Cell Transplant)"}],"paramType":"NUMBER","populationDescription":"All treated and eligible patients","reportingStatus":"POSTED","timeFrame":"First 100 days","title":"Day 100 TRM","type":"PRIMARY","unitOfMeasure":"percentage of participants"}